Coronary Artery Disease Therapeutics MarketSize and Trends

Coronary Artery Disease Therapeutics Market Drivers:-

The global market is expected to witness significant growth due to robust pipeline of drugs over the forecast period (2018-2026). For instance, hydroxychloroquine sulfate tablets sponsored by first affiliated hospital of Xi’an Jiaotong university, China is in the fourth phase of clinical trials, this drug suppresses symptoms of coronary artery disease. Atorvastatin sponsored by university health network, Toronto has completed phase two clinical trials in 2014, this drug reduces the risk of heart attack and myocardial infraction. PADMA 28 sponsored by University hospital Inselsiptal, Berne has completed phase 2 clinical trials in 2013, this drug has beneficial effect on arterial system, the autonomic nervous system and blood inflammatory markers in patients with coronary artery disease.

Furthermore, approval of new drugs for coronary artery disease is another factor driving growth of the coronary artery disease therapeutics market. For instance, in 2016, the U.S. FDA approved Yosprala (Aspirin and Omeprazole) by Aralez Pharmaceuticals, a Canada-based company, this drug is used to prevent cardiovascular diseases. In 2015, FDA approved Repatha by Amgen Inc. This drug is used to treat high cholesterol. In 2015, FDA approved Prestalia by Symplmed Pharmaceuticals LLC, this drug is used to treat hypertension for people suffering with heart disorders. Later in 2017, Prestalia was acquired by Marina Biotech Inc.